Antibiotics: Technologies and Global Markets

Published: December 2020

No. of Pages: 170

Price:

Single User License: US $ 5500 US $ 4125
Corporate User License: US $ 9504 US $ 7128

Report Description
Table of Contents

Report Scope:

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics. This report will also highlight the current and future market potentiality of antibiotics with detailed analysis of competitive environment between the companies. Drivers, restraints, opportunities, pricing analysis, impact of COVID-19, other infectious diseases and a regulatory scenario assessment will be covered in the current report. The report covers a market projection for 2025, and a market share for key players.

The report segments the market for antibiotics based on product type, route of administration, application and geography. Based on product type, the market is segmented into cell wall inhibitors, protein inhibitors, DNA inhibitors and other inhibitors (RNA, Mycolic Acid, Folic Acid). Based on route of administration, the market is segmented into oral and topical. The market is also presented based on application type, which is further segmented into human and veterinary.

By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. Detailed analysis of major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2025.

Report Includes:

- 28 data tables and 16 additional tables

- Comprehensive overview of the global market for antibiotics within the pharmaceutical industry

- Analyses of the global market trends, with data corresponding to market size for 2018-2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025

- Latest information on market growth drivers and opportunities, industry supply chain structure, regulatory developments, technological advancements, and demographic shifts shaping the overall antibiotics marketplace

- Evaluation of market growth during the forecast period, and deep dive of market share analysis data basis of product type, product, route of administration, end-user and geographical region

- Country specific data and analysis for the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries and South Africa

- Impact of COVID-19 on the pharmaceutical market for antibiotics and an outlook of short-term vs. long-term impacts of COVID-19 pandemic

- Identification of the companies best positioned to meet the global market demand for antibiotic drugs on the basis of their proprietary technologies, M&A deals, collaborations, JVs and other strategic alliances

- Detailed company profiles of the major global corporations, including Abbott, F. Hoffmann-La Roche AG, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Pfizer and Sanofi

Summary:

The global market for antibiotics was valued at $REDACTED in 2019. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED% to reach $REDACTED billion by 2025. The antibiotics market growth outlook is positive with significant growth potential for cell wall inhibitor and protein inhibitor antibiotic drugs. There is pressure on antibiotic drug manufacturers to offer antimicrobial-resistant drugs at affordable prices. At the same time, factors such as rising disposable incomes and increasing spending on healthcare in emerging markets, increasing grants from government agencies for antibiotic drugs research and development, and rising incidence of infectious diseases are contributing to the growth of the market.

Pharmaceutical companies and governments are increasingly working together in partnerships and collaborations to provide funding and implement incentive programs for the research and development (R&D) of antibiotics. These partnerships provide financial and technical assistance across different clinical development phases to the pharmaceutical companies. Various programs, such as the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), the Innovative Medicines Initiative’s (IMI’s) New Drugs for Bad Bugs (ND4BB) program, Biomedical Advanced Research and Development Authority’s (BARDA) Broad Spectrum Antimicrobials Program, and Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), have been implemented for the development of novel antibiotics by focusing on R&D gaps.

Additionally, The Davos Declaration was signed in January 2016 by more than 100 companies and trade associations which included Allergan, AstraZeneca, GSK, Pfizer and Sanofi. This declaration focused on investments in R&D to meet public health needs, reducing the development of antimicrobial resistance and improving access to antibiotics.

Pharmaceutical companies are increasingly adopting 3D printing technology for the discovery and development of new antibiotics to reduce manufacturing costs and increase production efficiency. For instance, in 2018, a 3D-printed fluorescence imaging box (PFIbox) was developed by McMaster University’s laboratory for antibiotics discovery. This box is capable of analyzing more than 6,000 samples of bacteria at a time and provides vital information on bacterial response.

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Overview of Antibiotics
Common Side Effects of Antibiotics
Classification of Antibiotics
Cell Wall Inhibitors
Protein Inhibitors
DNA Inhibitors
Other Antibiotic Classes
Overview of Gram-negative and Gram-positive Bacteria
Route of Administration
Trends in the Market for Antibiotics
Funding for New Antibiotic Development
Increasing Focus on Antibiotic Drug Development by Smaller Pharmaceutical Firms
Growing Public-Private Partnerships
Chapter 4 Market Dynamics
Market Drivers
Growth of the Global Pharmaceutical Market Driven by Antibiotics
Rise in Geriatric Population and Infection Rate
Increasing Prevalence of Hospital-acquired Infections
Improved Awareness about Diseases and their Antibiotics
Market Restraints
Antibiotic-resistant Infections
Genericization of Antibiotics and Drugs
Declining Research and Development (R&D) Investment
Side Effects of Antibiotics
Market Opportunities
Market Expansion into Emerging Countries
Development of Novel Antibacterial Agents
Chapter 5 Market Breakdown by Product
Global Market for Antibiotics by Product
Cell Wall Inhibitors
Protein Inhibitors
DNA Inhibitors
Other Types of Inhibitors
Chapter 6 Market Breakdown by Route of Administration
Global Market for Antibiotics by Route of Administration
Oral Antibiotics
Topical Antibiotics
Other Routes of Administration
Chapter 7 Market Breakdown by Region
Global Market for Antibiotics by Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Chapter 8 Impact of COVID-19 on the Pharmaceutical Industry
Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
Research and Development Changes
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in Pharma Industry
Pharmaceutical Industry Growth Slow-Down
Changes in Consumption Trends in Health-related Products
Chapter 9 Clinical Developments and Pipeline Products
Respiratory Tract Infections
Chapter 10 Value Chain Analysis
Introduction
China is a Becoming a Center of Microbial Threats
Chapter 11 Regulatory Scenario
FDA and International Regulation
Recent Regulatory Reforms
Ketek Case Study
Chapter 12 Competitive Landscape
Global Company Market Share Analysis
Mergers, Collaborations, Partnerships and Acquisitions
Chapter 13 Company Profiles
ABBOTT
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
JOHNSON & JOHNSON
MERCK & CO., INC.
MYLAN N.V.
PFIZER INC.
SANOFI
Chapter 14 Appendix: Acronyms

List of Tables
Summary Table A : Global Market for Antibiotics, by Product, Through 2025
Summary Table B : Global Market for Antibiotics, by Route of Administration, Through 2025
Table 1 : Major Differences Between Gram-positive and Gram-negative Organisms
Table 2 : Proportion of Resistant Strains, by WHO Region
Table 3 : Global Market for Antibiotics, by Product, Through 2025
Table 4 : Global Market for Cell Wall Inhibitors, by Region, Through 2025
Table 5 : Global Market for Protein Inhibitors, by Region, Through 2025
Table 6 : Global Market for DNA Inhibitors, by Region, Through 2025
Table 7 : Global Market for Other Types of Inhibitors, by Region, Through 2025
Table 8 : Global Market for Antibiotics, by Route of Administration, Through 2025
Table 9 : Global Market for Oral Antibiotics, by Region, Through 2025
Table 10 : Global Market for Topical Antibiotics, by Region, Through 2025
Table 11 : Global Market for Other Routes of Administration of Antibiotics, by Region, Through 2025
Table 12 : Global Market for Antibiotics, by Region, Through 2025
Table 13 : North American Market for Antibiotics, by Product, Through 2025
Table 14 : North American Market for Antibiotics, by Route of Administration, Through 2025
Table 15 : North American Market for Antibiotics, by Country, Through 2025
Table 16 : European Market for Antibiotics, by Product, Through 2025
Table 17 : European Market for Antibiotics, by Route of Administration, Through 2025
Table 18 : European Market for Antibiotics, by Country, Through 2025
Table 19 : Asia-Pacific Market for Antibiotics, by Product, Through 2025
Table 20 : Asia-Pacific Market for Antibiotics, by Route of Administration, Through 2025
Table 21 : Asia-Pacific Market for Antibiotics, by Country, Through 2025
Table 22 : Latin American Market for Antibiotics, by Product, Through 2025
Table 23 : Latin American Market for Antibiotics, by Route of Administration, Through 2025
Table 24 : Latin American Market for Antibiotics, by Country, Through 2025
Table 25 : Middle Eastern and African Market for Antibiotics, by Product, Through 2025
Table 26 : Middle Eastern and African Market for Antibiotics, by Route of Administration, Through 2025
Table 27 : Middle Eastern and African Market for Antibiotics, by Country, Through 2025
Table 28 : Antibiotics and Combinations in Global Clinical Development and the Pipeline
Table 29 : FDA-Approved Antibacterial Drugs, 2018
Table 30 : FDA-Approved Antibacterial Drugs, 2019
Table 31 : Abbott: Antibiotics Product Portfolio
Table 32 : F. Hoffmann-La Roche AG: Antibiotics Product Portfolio
Table 33 : GlaxoSmithKline Plc: Antibiotics Product Portfolio
Table 34 : Johnson & Johnson: Antibiotics Product Portfolio
Table 35 : Merck & Co., Inc.: Antibiotics Product Portfolio
Table 36 : Merck & Co., Inc.: Antibiotic Drugs Overview
Table 37 : Mylan N.V.: Antibiotics Product Portfolio
Table 38 : Pfizer Inc.: Antibiotics Product Portfolio
Table 39 : Pfizer Inc.: Antibiotic Drugs Overview
Table 40 : Sanofi: Antibiotics Product Portfolio
Table 41 : Sanofi S.A.: Antibiotic Drugs Overview
Table 42 : Acronyms Used in this Report

List of Figures
Summary Figure A : Global Market Shares of Antibiotics, by Product, 2019
Summary Figure B : Global Market Shares of Antibiotics, by Route of Administration, 2019
Figure 1 : Share of API Manufacturing Facilities for All Drugs, by Country/Region, August 2019
Figure 2 : Share of Population Aged 65 Years or Over, by Region, 2019
Figure 3 : Forecasted Share of Population Aged 65 Years or Over, by Region, 2050
Figure 4 : Increase in Aging Population, 2011 and 2050
Figure 5 : Distribution of Population with HAIS in the U.S., 2014
Figure 6 : Major Socioeconomic and Political Factors Contributing to Antibiotic Resistance
Figure 7 : Global Market Shares of Antibiotics, by Product, 2019
Figure 8 : Global Market for Cell Wall Inhibitors, 2018-2025
Figure 9 : Global Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
Figure 10 : Global Market for Cell Wall Inhibitors, by Region, 2018-2025
Figure 11 : Global Market for Protein Inhibitors, 2018-2025
Figure 12 : Global Market Shares of Antibiotics, by Protein Inhibitor, 2019
Figure 13 : Global Market for Protein Inhibitors, by Region, 2018-2025
Figure 14 : Global Market for DNA Inhibitors, 2018-2025
Figure 15 : Global Market Shares of Antibiotics, by DNA Inhibitor, 2019
Figure 16 : Global Market for DNA Inhibitors, by Region, 2018-2025
Figure 17 : Global Market for Other Types of Inhibitors, 2018-2025
Figure 18 : Global Market for Other Types of Inhibitors, by Region, 2018-2025
Figure 19 : Global Market Shares of Antibiotics, by Route of Administration, 2019
Figure 20 : Global Market for Oral Antibiotics, 2018-2025
Figure 21 : Global Market for Oral Antibiotics, by Region, 2018-2025
Figure 22 : Global Market for Topical Antibiotics, 2018-2025
Figure 23 : Global Market for Topical Antibiotics, by Region, 2018-2025
Figure 24 : Global Market for Other Routes of Administration of Antibiotics, 2018-2025
Figure 25 : Global Market for Other Routes of Administration of Antibiotics, by Region, 2018-2025
Figure 26 : Global Market Shares of Antibiotics, by Region, 2019
Figure 27 : North American Market Shares of Antibiotics, by Product, 2019
Figure 28 : North American Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
Figure 29 : North American Market Shares of Antibiotics, by Protein Inhibitor, 2019
Figure 30 : North American Market Shares of Antibiotics, by DNA Inhibitor, 2019
Figure 31 : North American Market Shares of Antibiotics, by Route of Administration, 2019
Figure 32 : North American Market Shares of Antibiotics, by Country, 2019
Figure 33 : U.S. Market for Antibiotics, 2018-2025
Figure 34 : Canadian Market for Antibiotics, 2018-2025
Figure 35 : Mexican Market for Antibiotics, 2018-2025
Figure 36 : European Market Shares of Antibiotics, by Product, 2019
Figure 37 : European Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
Figure 38 : European Market Shares of Antibiotics, by Protein Inhibitor, 2019
Figure 39 : European Market Shares of Antibiotics, by DNA Inhibitor, 2019
Figure 40 : European Market Shares of Antibiotics, by Route of Administration, 2019
Figure 41 : European Market Shares of Antibiotics, by Country, 2019
Figure 42 : German Market for Antibiotics, 2018-2025
Figure 43 : French Market for Antibiotics, 2018-2025
Figure 44 : U.K. Market for Antibiotics, 2018-2025
Figure 45 : Italian Market for Antibiotics, 2018-2025
Figure 46 : Spanish Market for Antibiotics, 2018-2025
Figure 47 : Rest of the European Market for Antibiotics, 2018-2025
Figure 48 : Asia-Pacific Market Shares of Antibiotics, by Product, 2019
Figure 49 : Asia-Pacific Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
Figure 50 : Asia-Pacific Market Shares of Antibiotics, by Protein Inhibitor, 2019
Figure 51 : Asia-Pacific Market Shares of Antibiotics, by DNA Inhibitor, 2019
Figure 52 : Asia-Pacific Market Shares of Antibiotics, by Route of Administration, 2019
Figure 53 : Asia-Pacific Market Shares of Antibiotics, by Country, 2019
Figure 54 : Japanese Market for Antibiotics, 2018-2025
Figure 55 : Chinese Market for Antibiotics, 2018-2025
Figure 56 : Indian Market for Antibiotics, 2018-2025
Figure 57 : Australia and New Zealand Market for Antibiotics, 2018-2025
Figure 58 : Rest of Asia-Pacific Market for Antibiotics, 2018-2025
Figure 59 : Latin American Market Shares of Antibiotics, by Product, 2019
Figure 60 : Latin American Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
Figure 61 : Latin American Market Shares of Antibiotics, by Protein Inhibitor, 2019
Figure 62 : Latin American Market Shares of Antibiotics, by DNA Inhibitor, 2019
Figure 63 : Latin American Market Shares of Antibiotics, by Route of Administration, 2019
Figure 64 : Latin American Market Shares of Antibiotics, by Country, 2019
Figure 65 : Brazilian Market for Antibiotics, 2018-2025
Figure 66 : Argentinian Market for Antibiotics, 2018-2025
Figure 67 : Rest of Latin American Market for Antibiotics, 2018-2025
Figure 68 : Middle Eastern and African Market Shares of Antibiotics, by Product, 2019
Figure 69 : Middle Eastern and African Market Shares of Antibiotics, by Cell Wall Inhibitor, 2019
Figure 70 : Middle Eastern and African Market Shares of Antibiotics, by Protein Inhibitor, 2019
Figure 71 : Middle Eastern and African Market Shares of Antibiotics, by DNA Inhibitor, 2019
Figure 72 : Middle Eastern and African Market Shares of Antibiotics, by Route of Administration, 2019
Figure 73 : Middle Eastern and African Market Shares of Antibiotics, by Country, 2019
Figure 74 : Market for Antibiotics in the GCC Countries, 2018-2025
Figure 75 : South African Market for Antibiotics, 2018-2025
Figure 76 : Rest of Middle Eastern and African Market for Antibiotics, 2018-2025
Figure 77 : Impact of COVID-19 on the Pharmaceutical Industry
Figure 78 : Global Market Shares of Antibiotics, by Manufacturer, 2019
Figure 79 : Abbott: Annual Revenue, 2016-2019
Figure 80 : Abbott: Revenue Shares, by Country/Region, 2019
Figure 81 : Abbott: Revenue Shares, by Business Unit, 2019
Figure 82 : F. Hoffmann-La Roche AG: Annual Revenue, 2016-2019
Figure 83 : F. Hoffmann-La Roche AG: Revenue Shares in Pharmaceutical Segment, by Country/Region, 2019
Figure 84 : F. Hoffmann-La Roche AG: Revenue Shares, by Business Segment, 2019
Figure 85 : GlaxoSmithKline Plc: Annual Revenue, 2016-2019
Figure 86 : GlaxoSmithKline Plc: Revenue Shares, by Pharmaceuticals, 2019
Figure 87 : Johnson & Johnson: Annual Revenue, 2016-2019
Figure 88 : Johnson & Johnson: Revenue Shares, by Region, 2019
Figure 89 : Johnson & Johnson: Revenue Shares, by Business Unit, 2019
Figure 90 : 90Merck & Co., Inc.: Annual Revenue, 2016-2019
Figure 91 : Merck & Co., Inc.: Revenue Shares, by Region, 2019
Figure 92 : Merck & Co., Inc.: Revenue Shares, by Business Unit, 2019
Figure 93 : Mylan N.V.: Annual Revenue, 2016-2019
Figure 94 : Mylan N.V.: Revenue Shares, by Region, 2019
Figure 95 : Mylan N.V.: Revenue Shares, by Business Unit, 2019
Figure 96 : Pfizer Inc.: Annual Revenue, 2016-2019
Figure 97 : Pfizer Inc.: Revenue Shares, by Country/Region, 2019
Figure 98 : Pfizer Inc.: Revenue Shares, by Business Segment, 2019
Figure 99 : Sanofi: Annual Revenue, 2016-2019
Figure 100 : Sanofi: Revenue Shares, by Region/Country, 2019
Figure 101 : Sanofi: Revenue Shares, by Business Segment, 2019

Write comment about above report:

Published By: BCC Research

Product Code: BCC Research1263

Related Reports

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

(R)-1,3-butanediol Market Global Review and Outlook by 5 Companies (Daicel Chemical, Chiracon GmbH, Camphor Technologies etc.), by Application (Antibiotics, Pheromone, Others) (R)-1,3-butanediol report is in-depth investigation for Global market. (R)-1,3-butanediol market was valued at USD XX million Global in 2018 and is forecasted to reach USD XXX million by 2024, with a CAGR of xx% during the 2018-2024.The scope of (...

We are on:

Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
- Upto 24 hrs - working days
- Upto 48 hrs max - weekends and public holidays

Need Help?

Name *

Email *

Phone *

Country *

Subject *

Comments *